Wegovy and hypertension: what clinical trials and UK guidance actually show

What the STEP trials found on blood pressure

The cardiovascular picture that emerged from the STEP programme is more than a by-product of weight loss. In STEP 1, participants without diabetes who received semaglutide 2.4 mg saw average systolic blood pressure fall by roughly 6 mmHg compared with placebo over 68 weeks. Diastolic pressure also fell, though by a smaller margin. Researchers noted that some of this reduction appeared independent of the weight lost, suggesting a direct vascular effect of GLP-1 receptor activation, not only a downstream consequence of eating less.

The SELECT cardiovascular outcomes trial went further. It enrolled over 17,000 adults with pre-existing cardiovascular disease and overweight or obesity, and semaglutide reduced the risk of major cardiovascular events (heart attack, stroke, or cardiovascular death) by around 20 % compared with placebo. That trial was the basis for Wegovy's additional UK authorisation covering cardiovascular risk reduction in eligible adults. The NHS medicines page for semaglutide sets out the current UK-licensed indications in plain language.

None of this replaces existing antihypertensive treatment. What it does mean is that weight management with semaglutide carries meaningful evidence of blood-pressure benefit, not merely the theoretical benefit of any weight loss. That distinction matters when deciding whether to discuss Wegovy with a clinician.

Hypertension as a qualifying condition for Wegovy

Under the UK licence, Wegovy is approved for adults with a BMI of 30 or above, or for adults with a BMI of 27 to 29.9 who have at least one weight-related health condition. High blood pressure is explicitly listed among the conditions that satisfy this second threshold. In practice, that means someone with a BMI of 28 and a hypertension diagnosis could be clinically eligible, though BMI alone never settles the question. A prescriber reviews the whole picture: other medicines you take, kidney function, cardiovascular history, and whether your blood pressure is currently controlled.

NICE's recommendation for semaglutide (Wegovy) under Technology Appraisal TA875 applies within specialist weight management services and carries a two-year maximum, with stricter BMI thresholds than the licence itself. Private prescribing follows the licence rather than the NICE pathway. The distinction matters: private patients are not restricted to specialist-only access or the two-year cap, but the prescriber still makes an individual clinical judgement each time treatment is reviewed.

If your blood pressure is poorly controlled or very high, a prescriber may want GP input before starting. That is not a barrier, it is good clinical practice, and it is reflected in how our clinical team approaches reviews.

Practical points if you take blood pressure medication

This is a question our prescribers hear regularly: if Wegovy lowers blood pressure and you are already on antihypertensives, what happens? In some people, blood pressure falls enough that existing medication needs reducing. That is not a crisis, it is something to monitor. It does, however, mean your GP should know you have started Wegovy, both so they can track readings and adjust doses if needed. Good clinical services notify GPs as standard; at nume, GP notification is part of our process, in line with GPhC guidance.

The interaction is rarely dangerous, but symptomatic low blood pressure (lightheadedness on standing, feeling faint) is worth reporting promptly. If you ever feel unwell after a dose increase, contact your prescriber before your next injection rather than waiting for a scheduled check-in. Our support team is available seven days a week.

Wegovy's most common side effects are gastrointestinal rather than cardiovascular: nausea, loose stools, and reflux are the most frequently reported, typically peaking in the first weeks of each new dose. They settle for most people. The full Wegovy overview covers what to expect across the titration schedule. There is also emerging evidence around other body systems; for example, some patients ask about semaglutide alongside antidepressants, and people with longer-standing cardiovascular risk factors sometimes raise questions about how semaglutide may affect vision, which is worth reading about alongside the broader picture of semaglutide and vision changes.

The private route versus NHS access for people with hypertension

On the NHS, Wegovy is available via specialist weight management services under TA875, and waiting lists in many areas run to months or longer. NHS tirzepatide (Mounjaro) access through GP practices opened from June 2025 for the highest-risk cohort, with further phases rolling out. Neither route is quick if you are managing hypertension and looking to act now.

Private treatment through a regulated online pharmacy offers an alternative (no referral, no waiting list) subject to clinical suitability confirmed at consultation. You can check what Wegovy costs privately to understand what a realistic monthly spend looks like, bearing in mind that a legitimate private price includes the prescription, clinical review, and dispensing. If cost is a factor, it is worth knowing that our Wegovy Black Friday deals page is worth checking if you want to reduce the upfront cost of starting treatment; a prescriber can help you weigh the options.

Treatment is a prescription-only medicine in every route. If you would like a clinical assessment to see whether semaglutide is appropriate for your situation, you can start a free consultation with our prescribers today.